

## *New Jersey's Opioid Settlements*

The United States is in the **midst of a crisis** on its streets and in its communities as **overdoses, homelessness, and disorder reach record levels**. Yet settlement proceeds secured by the State of New Jersey present an **unprecedented opportunity for generational investment** in treatment capacity for chronic substance abuse (CSA) and severe mental illness (SMI).

New Jersey is set to receive **more than \$1.3 billion** (\$1,336,353,482.65) in opioid settlement funds—equal to one-fifth of the state's share of the monumental Tobacco Master Settlement Agreement.<sup>1</sup> With twenty-one separate settlements and payments spread out over decades, the funds are **at risk of being squandered** through ad-hoc allocations to **diffuse and disorganized efforts**.

The state must ensure that this opportunity for treatment investment is not underutilized. **New Jersey can make targeted investments in treatment capacity** that will **honor those who suffered** in the opioid crisis and **ensure accessible care** for decades to come.

New Jersey reserves half (\$692,605,207.34) of the opioid funds for use by the state and allocates the remainder to subdivisions.<sup>2</sup> <sup>i</sup> The Department of Health Services has ultimate allocation authority of the state's share of funds from the Opioid Recovery and Remediation Fund, with the advice of the 16-person Opioid Recovery and Remediation Advisory Council.<sup>3</sup> <sup>4</sup> The latest report shows the state allocated \$37 million in the last fiscal year, including more than \$12 million for various harm reduction initiatives and \$5 million for homeless shelters pending permanent housing placement.<sup>5</sup> **The state should amend statute and vest ultimate allocation authority in the legislature in order to prioritize treatment infrastructure investments.**

The state must rein in the misallocation of these funds and prioritize investments in comprehensive treatment networks. **Three priorities** (Certified Community Behavioral Health Clinics, secure psychiatric beds, and community SMI/CSA response) **will ensure these funds have the largest impact** on New Jersey.

---

<sup>i</sup> With the exception of the McKinsey, Publicis, and Insys settlements, in which the state controls 100 percent of funds.

## Certified Community Behavioral Health Clinics (CCBHCs)

CCBHCs, designed to ensure access to coordinated comprehensive behavioral health care, have stable funding and are supported by all recent presidential administrations. CCBHCs are a key response to the opioid crisis and can augment other services such as police crisis response teams, homelessness outreach and services, and outpatient psychiatric commitment services.

- **Solution: Fund the development and expansion of CCBHCs.**
  - o Expand the CCBHC footprint with an emphasis on a team-based approach to co-occurring disorders.
  - o Create a stepped approach to SMI/CSA treatment with services provided by the CCBHCs.
  - o Require CCBHCs to offer specific care pathways to meet the needs of individuals with co-occurring disorders.

## State Psychiatric Hospitals

Inpatient beds in secure facilities are critical for serving the highest-acuity psychiatric patients. New Jersey currently has only **11.9 state psychiatric beds** per 100,000 people available for civil (i.e., non-criminal) patients.<sup>6,7</sup> Treatment Advocacy Center recommends a rate of 30-60 beds per 100,000. Even counting non-public secure psychiatric beds, New Jersey still falls short of the minimum.<sup>8</sup> Secure beds are a costly but necessary expenditure to protect patients with severe psychiatric disorders and the public at large.

- **Solution: Fund the expansion of civil psychiatric beds.**
  - o Invest in expanding state hospital capacity.
  - o Move forensic (criminal) commitments to a jail-based restoration facility.
  - o Apply for one of several Section 1115(a) waivers to expand Medicaid reimbursement for institutions for mental diseases (IMDs).

## Inpatient Stabilization Centers and Mobile Crisis Teams

Emergency departments (EDs) are supposed to be a last resort for times of true emergencies, but are increasingly used for all types of immediate-need medical care. This is especially true for low- to medium-acuity mental health crises. In order for CCBHCs and state psychiatric bed expansions to have the largest impact, there must be an immediate triage of low-acuity patients from higher-need patients, or else investments in these facilities will be drowned out, overburdened, and underutilized by those that need them most, just like emergency departments.

- **Solution: Fund community-based mental health response resources.**
  - Expand community-based recovery centers, including voluntary short-term respite housing, especially for young adults.
  - Leverage CCBHC resources to develop comprehensive mobile crisis response teams in conjunction with police crisis intervention teams (CIT).
  - Support integration of community resources with crisis networks such as the Lifeline to support those in need or provide guidance for concerned loved ones.

## NEW JERSEY

[Download all New Jersey opioid settlement documents](#)

[View settlement fund dashboard](#)

STATE-CONTROLLED FUNDS	ALL FUNDS	2025 EOY FUNDS RECEIVED - STATE	2025 EOY FUNDS RECEIVED - ALL	Av. Receipt (All Funds) / Yr (*20)
\$692,605,207.34	\$1,336,353,482.65	\$250,176,456.71	\$453,862,952.48	\$66,817,674.13

### 2021 National Opioid Settlement

*New Jersey v. Distributors*

- [Final Consent Judgment](#)
  - [Exhibit A "Distributor Settlement Agreement"](#)
  - [Exhibit B "Memorandum of Understanding between the State of New Jersey and Local Governments on Opioid Litigation Recoveries"](#)
- Matthew J. Platkin, Acting Attorney General of New Jersey, on behalf of the State of New Jersey, and Sean P. Neafsey, Acting Director of the New Jersey Division of Consumer Affairs, v. McKesson Corporation, et al., Superior Court of New Jersey, Chancery Division, Mercer County, Case No. MER-C-31-22

*New Jersey v. Janssen*

- [Final Consent Judgment](#)
  - [Exhibit A "Janssen Settlement Agreement"](#)
  - [Exhibit B "Memorandum of Understanding between the State of New Jersey and Local Governments on Opioid Litigation Recoveries"](#)
- Matthew J. Platkin, Acting Attorney General of New Jersey, on behalf of the State of New Jersey, and Sean P. Neafsey, Acting Director of the New Jersey Division of Consumer Affairs, v. Janssen Pharmaceuticals, Inc., et al., Superior Court of New Jersey, Chancery Division, Mercer County, Case No. MER-C-80-18

### 2022 National Opioid Settlement

*New Jersey v. CVS*

- [Final Consent Judgment](#)
  - [Exhibit A "agreement dated as of December 9 2022"](#)
  - [Exhibit B "Memorandum of Understanding between the State of New Jersey and Local Governments on Opioid Litigation Recoveries"](#)
- Matthew J. Platkin, Attorney General of New Jersey, on behalf of the State of New Jersey, and Cari Fais, Acting Director of the New Jersey Division of Consumer Affairs, v. CVS Pharmacy, Inc., et al., Superior Court of New Jersey, Chancery Division, Mercer County, Case No. MER-C-85-23

*New Jersey v. Walgreens*

- [Final Consent Judgment](#)
  - [Exhibit A “agreement dated as of December 9 2022”](#)
  - [Exhibit B “Memorandum of Understanding between the State of New Jersey and Local Governments on Opioid Litigation Recoveries”](#)
- Matthew J. Platkin, Attorney General of New Jersey, on behalf of the State of New Jersey, and Cari Fais, Acting Director of the New Jersey Division of Consumer Affairs, v. CVS Pharmacy, Inc., et al., Superior Court of New Jersey, Chancery Division, Mercer County, Case No. MER-C-85-23

*New Jersey v. Walmart*

- [Final Consent Judgment](#)
  - [Exhibit A “agreement dated as of November 14 2022”](#)
  - [Exhibit B “Memorandum of Understanding between the State of New Jersey and Local Governments on Opioid Litigation Recoveries”](#)
- Matthew J. Platkin, Attorney General of New Jersey, on behalf of the State of New Jersey, and Cari Fais, Acting Director of the New Jersey Division of Consumer Affairs, v. CVS Pharmacy, Inc., et al., Superior Court of New Jersey, Chancery Division, Mercer County, Case No. MER-C-85-23

*New Jersey v. Allergan*

- [Final Consent Judgment](#)
  - [Exhibit A “Allergan Public Global Opioid Settlement Agreement”](#)
  - [Exhibit B “Memorandum of Understanding between the State of New Jersey and Local Governments on Opioid Litigation Recoveries”](#)
- Matthew J. Platkin, Attorney General of New Jersey, on behalf of the State of New Jersey, and Cari Fais, Acting Director of the New Jersey Division of Consumer Affairs, v. Allergan Finance, LLC, f/k/a Actavis, Inc., f/k/a Watson Pharmaceuticals, Inc., et al., Superior Court of New Jersey, Chancery Division, Mercer County, Case No. MER-C-61-23

*New Jersey v. Teva*

- [Final Consent Judgment](#)
  - [Exhibit A “Teva Global Opioid Settlement Agreement”](#)
  - [Exhibit B “Memorandum of Understanding between the State of New Jersey and Local Governments on Opioid Litigation Recoveries”](#)
- Matthew J. Platkin, Attorney General of New Jersey, on behalf of the State of New Jersey, and Cari Fais, Acting Director of the New Jersey Division of Consumer Affairs, v. Allergan Finance, LLC, f/k/a Actavis, Inc., f/k/a Watson Pharmaceuticals, Inc., et al., Superior Court of New Jersey, Chancery Division, Mercer County, Case No. MER-C-61-23

## Other Coalition Opioid Settlements

### *New Jersey v. McKinsey*

- [Final Consent Judgment](#)
- [McKinsey Allocation Amounts](#)
- Gurbir S. Grewal, Attorney General of the State of New Jersey, and Sean Neafsey, Acting Director of the New Jersey Division of Consumer Affairs, v. McKinsey & Company, Inc. United States, Superior Court of New Jersey, Chancery Division, Mercer County, Case No. MER-C-13-21

### *New Jersey v. Mallinckrodt*

- [NOAT II Agreement](#)
- [Statewide Abatement Agreement](#)
- [Notice of Abatement Distribution](#)
- [Supplemental Notice of Abatement Distribution \(Reallocation\) \(Moorestown Township\)](#)

### *New Jersey v. Publicis*

- [Final Consent Judgment](#)
- Matthew J. Platkin, Attorney General of New Jersey, on behalf of the State of New Jersey, and Cari Fais, Acting Director of the New Jersey Division of Consumer Affairs, v. Publicis Health, LLC, Superior Court of New Jersey, Chancery Division, Mercer County, Case No. MER-C-10-24

### *New Jersey v. Endo*

- [Global Public Trust Agreement](#)
- [Notice of Abatement Distribution](#)

## 2025 National Settlements

### *New Jersey v. Purdue*

- [missing documentation]
- Gurbir S. Grewal, et al. v. Purdue Pharma L.P., et al., Superior Court New Jersey Chancery Division, Essex County, Case No. ESX-C-245-17 [unconfirmed]

### *New Jersey v. Mylan*

- [missing documentation]

### *New Jersey v. Hikma*

- [missing documentation]

### *New Jersey v. Amneal*

- [missing documentation]

### *New Jersey v. Apotex*

- [missing documentation]

*New Jersey v. Indivior*

- [missing documentation]

*New Jersey v. Sun Pharmaceuticals*

- [missing documentation]

*New Jersey v. Alvogen*

- [missing documentation]

*New Jersey v. Zydus*

- [missing documentation]

### Independent Settlements

---

<sup>1</sup> KFF. "Actual Tobacco Settlement Payments Received by the States (in millions)." Accessed 8 September 2025.

<https://www.kff.org/health-costs/state-indicator/tobacco-settlement-payments>.

<sup>2</sup> "Memorandum of Agreement between the State of New Jersey and Local Governments on Opioid Litigation Recoveries."

<https://drive.google.com/file/d/TVacim66sbSt0EZBp5kRkVwUIQdFm4s1A/view?usp=sharing>.

<sup>3</sup> New Jersey Revised Statutes § 26:2G-39.

<https://lis.njleg.state.nj.us/nxt/gateway.dll?f=templates&fn=default.htm&vid=Publish%3A10.1048%2FEnu>.

<sup>4</sup> New Jersey Revised Statutes § 26:2G-40.

<https://lis.njleg.state.nj.us/nxt/gateway.dll?f=templates&fn=default.htm&vid=Publish%3A10.1048%2FEnu>.

<sup>5</sup> New Jersey Department of Health Services, "New Jersey State Annual Opioid Abatement Report 2024."

<https://www.nj.gov/opioidfunds/documents/reports/2024A%20-%20New%20Jersey%20State%20Opioid%20Settlement%20Funding%20Report.pdf>.

<sup>6</sup> Treatment Advocacy Center, "New Jersey Psychiatric Beds Report." 2023. <https://www.tac.org/wp-content/uploads/2023/10/NewJerseybedsinformation.pdf>.

<sup>7</sup> United States Census Bureau, "2023 American Community Survey – Total Population."

[https://data.census.gov/table/ACSST1Y2023.B01003?q=population&t=Population+Total&g=010XX00US\\$0400000](https://data.census.gov/table/ACSST1Y2023.B01003?q=population&t=Population+Total&g=010XX00US$0400000).

<sup>8</sup> Silver, Shanti, "Estimating Psychiatric Bed Need in the United States," p. 2-4. Treatment Advocacy Center Office of Research and Public Affairs. January 2024. [https://www.tac.org/wp-content/uploads/2024/03/TAC\\_ORPA\\_ResearchSummary1.24.pdf](https://www.tac.org/wp-content/uploads/2024/03/TAC_ORPA_ResearchSummary1.24.pdf).